Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

148.23USD
14 Dec 2018
Change (% chg)

$-2.63 (-1.74%)
Prev Close
$150.86
Open
$149.02
Day's High
$150.37
Day's Low
$147.72
Volume
739,759
Avg. Vol
529,973
52-wk High
$197.00
52-wk Low
$142.83

Latest Key Developments (Source: Significant Developments)

Editas Medicine Announces FDA Acceptance Of IND Application For EDIT-101
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR EDIT-101.EDITAS MEDICINE INC - EARNS $25 MILLION MILESTONE FOR IND ACCEPTANCE FROM PARTNER ALLERGAN.EDITAS MEDICINE - CO, UNIT OF ALLERGAN EXPECT TO ENROLL 10 TO 20 PATIENTS IN PHASE 1/2 OPEN LABEL, DOSE ESCALATION STUDY TO EVALUATE EDIT-101.  Full Article

Allergan Makes New Appointments To Finance Leadership Team
Monday, 26 Nov 2018 

Allergan plc ::ALLERGAN MAKES NEW APPOINTMENTS TO FINANCE LEADERSHIP TEAM.ALLERGAN PLC - MANISHA NARASIMHAN, PHD, JOINS AS VP, INVESTOR RELATIONS & STRATEGIC INITIATIVES.ALLERGAN PLC - DAPHNE KARYDAS NAMED SENIOR VP, CORPORATE FINANCIAL PLANNING & ANALYSIS AND STRATEGY.ALLERGAN PLC - MANISHA NARASIMHAN TO JOIN CO AS VICE PRESIDENT OF INVESTOR RELATIONS AND STRATEGIC INITIATIVES, EFFECTIVE DECEMBER 10, 2018.  Full Article

Elite Pharmaceuticals Gets FDA Approval For Generic Version Of Allergan's Pain Treatment Tablets
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Elite Pharmaceuticals Inc ::ELITE PHARMACEUTICALS RECEIVES FDA APPROVAL FOR HYDROCODONE AND ACETAMINOPHEN COMBO.ELITE PHARMACEUTICALS - GOT FDA APPROVAL FOR APPLICATION FOR GENERIC VERSION OF NORCO (HYDROCODONE BITARTRATE & ACETAMINOPHEN TABLETS, USP CII) TABLETS.  Full Article

Allergan Announces FDA Acceptance Of Supplemental New Drug Application For Avycaz
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Allergan plc ::ALLERGAN ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR AVYCAZ® (CEFTAZIDIME AND AVIBACTAM).ALLERGAN ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR AVYCAZ® (CEFTAZIDIME AND AVIBACTAM).ALLERGAN PLC - APPLICATION SEEKS TO EXPAND AVYCAZ LABEL TO INCLUDE TREATMENT OF CUTI AND CIAI IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER.ALLERGAN PLC - U.S. FOOD AND DRUG ADMINISTRATION HAS ACCEPTED FOR REVIEW COMPANY'S SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR AVYCAZ.  Full Article

Allergan Reports Third Quarter 2018 Results
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Allergan plc ::ALLERGAN REPORTS THIRD QUARTER 2018 RESULTS INCLUDING GAAP NET REVENUES OF $3.9 BILLION.Q3 GAAP LOSS PER SHARE $0.11.Q3 EARNINGS PER SHARE VIEW $4.04 -- THOMSON REUTERS I/B/E/S.RAISES FULL-YEAR 2018 NET REVENUE AND NON-GAAP PERFORMANCE NET INCOME PER SHARE GUIDANCE.QTRLY NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $4.25.RESTASIS NET REVENUES IN Q3 OF 2018 WERE $298.0 MILLION, A DECREASE OF 18.8 PERCENT VERSUS PRIOR YEAR QUARTER.IN Q3, INTERNATIONAL NET REVS WERE NEGATIVELY IMPACTED BY A RECALL OF OZURDEX IN CERTAIN INTERNATIONAL MARKETS.SEES 2018 GAAP TOTAL NET REVENUES OF ABOUT $15.575 - $15.725 BILLION.ALLERGAN - BOTOX COSMETIC NET REVS IN Q3 WERE $163.4 MILLION, AN INCREASE OF 32.5 PERCENT VERSUS PRIOR YEAR QUARTER EXCLUDING FOREIGN EXCHANGE IMPACT.SEES 2018 NON-GAAP TOTAL NET REVENUES OF ABOUT $15.550 - $15.700 BILLION.SEES 2018 GAAP RESEARCH AND DEVELOPMENT EXPENSE OF ABOUT $2.3 BILLION.SEES 2018 NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE OF ABOUT $1.55 BILLION.SEES 2018 NON-GAAP EARNINGS PER SHARE OF ABOUT $16.20 - $16.60.SEES 2018 NET LOSS PER SHARE OF LOSS OF $3.36 TO LOSS OF $2.95.SEES 2018 GAAP CASH FLOW FROM OPERATIONS OF ABOUT $5.2 BILLION.Q3 REVENUE VIEW $3.89 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $16.38, REVENUE VIEW $15.61 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Allergan Declares Q4 Cash Dividend Of $0.72 Per Ordinary Share
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Allergan plc ::ALLERGAN DECLARES FOURTH QUARTER 2018 CASH DIVIDEND OF $0.72 PER ORDINARY SHARE.  Full Article

Allergan To Showcase Continued Eye Care Innovation With New Datag
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Allergan plc ::ALLERGAN TO SHOWCASE CONTINUED EYE CARE INNOVATION WITH NEW DATA ON INVESTIGATIONAL MEDICINES AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING.  Full Article

Allergan Launches Personalized Study Approach For Clinical Research Programs In Inflammatory Bowel Disease
Friday, 5 Oct 2018 

Oct 5 (Reuters) - Allergan plc ::ALLERGAN LAUNCHES PERSONALIZED STUDY APPROACH FOR CLINICAL RESEARCH PROGRAMS IN INFLAMMATORY BOWEL DISEASE.ALLERGAN - PROGRAMS WILL EVALUATE SAFETY AND EFFICACY OF BRAZIKUMAB AND POTENTIAL CORRELATION BETWEEN BIOMARKERS AND PATIENT OUTCOMES WITH BRAZIKUMAB.  Full Article

Allergan Receives FDA Clearance To Treat Area Below Jawline With Coolsculpting
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Allergan plc ::ALLERGAN RECEIVES FDA CLEARANCE TO TREAT AREA BELOW THE JAWLINE WITH COOLSCULPTING®.ALLERGAN PLC - FDA CLEARANCE WAS EXPANDED TO INCLUDE PATIENTS WITH A BMI OF UP TO 46.2 WHEN TREATING SUBMENTAL AND SUBMANDIBULAR AREAS.  Full Article

Almirall Receives FDA Approval For Seysara (Sarecycline)
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Almirall SA ::RECEIVES FDA APPROVAL FOR SEYSARA (SARECYCLINE).WILL BE LAUNCHING SEYSARA IN JANUARY 2019 IN US MARKET AND EXPECTS PEAK SALES OF SEYSARA BETWEEN $150 MILLION TO $200 MILLION.SEYSARA TREATS INFLAMMATORY LESIONS OF ACNE IN PATIENTS 9 YEARS OF AGE AND OLDER.NEW PRODUCT COMES FROM ALLERGAN U.S. MEDICAL DERMATOLOGY ACQUISITION AND ITS APPROVAL IS AHEAD OF PLAN.  Full Article

UPDATE 2-Revance Therapeutics' Botox rival succeeds in late-stage trial

Dec 4 A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.